The FDA approved Eli Lilly’s Foundayo (orforglipron) on April 1, 2026, making it the first oral GLP-1 receptor agonist approved for weight loss. Lilly began shipping through its LillyDirect channel on April 9, with retail pharmacy availability expanding nationwide. The self-pay price starts at $149 per month, roughly 85% below injectable GLP-1s like Wegovy and Zepbound, which list at $1,000 or more before rebates.
Unlike existing injectable GLP-1s, Foundayo is a once-daily pill with no food or water restrictions. In the ATTAIN-1 trial, patients on the highest dose lost an average of 12.4% of body weight (27.3 pounds) over 72 weeks, with improvements in waist circumference, triglycerides, and systolic blood pressure.
Who It Affects
Self-insured employer health plans are the primary exposure. Roughly half of employer-sponsored plans currently exclude anti-obesity medications. At $1,000-plus per month for injectables, that exclusion was defensible on cost grounds. At $149, the math changes. Public entities, school districts, and hospital systems that self-fund their employee health benefits face the same decision, compounded by Morgan Lewis’s January 2026 analysis warning that ERISA plans covering GLP-1s for diabetes but excluding them for obesity face growing ADA and Mental Health Parity Act scrutiny.
The Reserve Mechanism
The operative reserve driver here is frequency and the expected claim ratio used in aggregate stop-loss pricing. Injectable GLP-1s carried two natural demand suppressors: needle aversion and sticker shock. Foundayo removes both. Plans that add coverage should expect a significant increase in the number of members filling GLP-1 prescriptions (frequency), which flows directly into pharmacy per-member-per-month (PMPM) cost projections.
The severity picture is more nuanced. At $149 per month, per-claimant cost is far lower than injectable alternatives. But adherence data suggests only about 1 in 12 patients remain on a GLP-1 for obesity at three years, which means the first 12 to 18 months of coverage will carry a disproportionate share of the total cost as new starts exceed discontinuations. This front-loading effect can distort the expected claim ratio used in Bornhuetter-Ferguson projections for the current plan year.
For stop-loss specifically, the concentration risk matters. A handful of high-utilization members on GLP-1s (particularly those on both Foundayo and an injectable) can push individual claims toward the specific attachment point. Stop-loss carriers are already quoting GLP-1-adjusted specific attachment factors, and aggregate corridors may need widening. Plans that maintain exclusions avoid the pharmacy cost but take on litigation risk, which shows up in a different reserve line entirely.
What to Ask Your Actuary
- If we add Foundayo to the formulary at $149 per month, what is the projected increase in pharmacy PMPM, and how does that affect our specific and aggregate stop-loss attachment points at the next renewal?
- What utilization rate should we model for an oral GLP-1 versus the injectable uptake we have observed, and how does the three-year discontinuation curve affect the development tail on these claims?
- Should we be modeling GLP-1 pharmacy spend as a separate cost bucket for stop-loss negotiations, given the concentration risk in a small number of high-utilization members?
What to Watch Next
Two developments will clarify the reserve picture. First, whether stop-loss carriers issue mid-year rate adjustments or revised attachment-point guidance once Foundayo uptake data becomes available in Q3 2026. Second, whether the EEOC or a private plaintiff brings the first ADA enforcement action against a self-insured plan that excludes oral GLP-1s for obesity while covering the same drug class for diabetes. Either event would shift the cost calculus further toward coverage, and toward higher pharmacy PMPM assumptions across the self-insured market.